Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 28, 2009 (Fiscal Q3 2009)
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used for treating solid tumors. The company operates globally with subsidiaries in Europe, Asia, and the Americas. As of March 31, 2009, 164 CyberKnife systems were installed at customer sites.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2008 |
|---|---|---|---|
| Total Net Revenue | $61,301 | $174,795 | $159,442 |
| Gross Profit | $30,362 | $88,200 | $80,056 |
| Gross Margin | 49.5% | 50.5% | 50.2% |
| Operating Income (Loss) | $862 | $(2,743) | $(354) |
| Net Income (Loss) | $1,216 | $(613) | $5,192 |
| Diluted EPS | $0.02 | $(0.01) | $0.09 |
| Cash and Cash Equivalents (End of Period) | $33,907 (as of Mar 31, 2009) | ||
| Net Cash Used in Operating Activities | $(9,927) (Nine Months 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 4.3% for the three months ended March 31, 2009, compared to the same period in 2008, driven by a 62.5% increase in service revenue. Product revenue remained relatively flat ($41.0M vs $40.7M).
- Profitability Shift: The company reported a net income of $1.2 million for the quarter, compared to $584,000 in the prior year quarter. However, for the nine-month period, the company reported a net loss of $613,000, a significant decline from the $5.2 million net income in the prior year.
- Inventory Write-downs: The company recorded $2.6 million in inventory write-downs during the nine months ended March 31, 2009, primarily due to improved inventory processes and the release of CyberKnife system version 8.5, which identified excess and obsolete inventory.
- Restructuring Costs: A "Workforce Alignment Plan" announced in January 2009 resulted in the reduction of approximately 60 positions (13% of the U.S. workforce), incurring $1.6 million in severance expenses during the quarter.
- Investment Volatility: Other income, net, decreased due to lower interest rates and unrealized losses on auction-rate securities (ARS), partially offset by gains on a put option related to ARS.
Guidance, Outlook, and Risks
- Backlog: Total backlog was $591.2 million as of March 31, 2009, consisting of $425.2 million in non-contingent backlog and $166.0 million in contingent backlog. Management anticipates recognition over the next five years.
- Liquidity: The company holds $33.9 million in cash and cash equivalents. Management believes current resources are sufficient for operations for at least the next 12 months. A secured line of credit with UBS (up to 75% of ARS par value) is available but currently unused.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting related to revenue recognition and inventory handling. Remediation efforts are ongoing, including hiring qualified personnel and strengthening processes. Management concluded that disclosure controls and procedures were not effective as of March 31, 2009.
- Regulatory and Market Risks: Risks include dependence on single-source suppliers, potential delays in FDA or international regulatory clearances for new products, and changes in Medicare reimbursement rates and CPT codes which could impact physician adoption.
- Investment Risk: The company holds $22.4 million par value of auction-rate securities (ARS) which have failed to auction. These are carried at a fair value of $18.5 million. A settlement agreement with UBS provides an option to sell these at par value between June 2010 and July 2012.
Key Facts for Investor Verification
- Revenue Recognition Adjustments: Verify the impact of adjustments recorded in Q3 2009 related to the remediation of revenue recognition material weaknesses.
- Inventory Valuation: Confirm the adequacy of the $2.6 million inventory reserve and the status of the inventory investigation concluded in Q1 2009.
- ARS Liquidity: Monitor the status of the $22.4 million auction-rate securities and the timeline for exercising the put option with UBS.
- Backlog Conversion: Assess the probability of converting the $166 million contingent backlog into recognized revenue, given potential regulatory or financing hurdles.
- Cost Savings Realization: Track the realization of cost savings from the Workforce Alignment Plan, expected to begin in fiscal year 2010.